Release date: 25 April 2018
Promoter – Financial Intermediary
BAVARIAN NORDIC A/SLocation
Description
This project will support Bavarian Nordic, a fully integrated Danish biotechnology company focused on the development, manufacturing and commercialisation of cancer immunotherapies and vaccines for infectious diseases. Financing is required for capital expenditure investments in Denmark.
Objectives
The project supports the company's investments into a new fill-finish manufacturing facility. The investments cover the operational expenditure (OPEX) and capital expenditure (CAPEX) costs to construct, furnish and validate the new manufacturing facility to a commercial level. By co-investing in this project, the Bank contributes to fostering the generation of scientific knowledge and acumen within Europe, in addition to creating skilled employment opportunities.
Sector(s)
- Industry - Manufacturing
Proposed EIB finance (Approximate amount)
EUR 30 million
Total cost (Approximate amount)
EUR 98 million
Environmental aspects
The project falls under the annex II of the Environmental Impact Assessment (EIA) directive (2014/52/EU), referring to the manufacture of pharmaceutical products. The project has been screened by the competent authorities and there is no EIA required. Full environmental details will be assessed during the appraisal.
Procurement
The promoter is a private company not operating in the utilities sector and is thus not covered by EU Directives on procurement.
Status
Signed - 9/08/2018
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).